ENVARSUS 4 mg, extended-release tablet 30 tablets
Active ingredients: Tacrolimus, Tacrolimus hydrate
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ENVARSUS 4 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- 3 plaquette(s) thermoformée(s) PVC de 10 comprimé(s)
- Marketing authorisation holder
- CHIESI FARMACEUTICI
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 20 Aug 2015
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64349915CIP73000126CIP133400930001264Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TACROLIMUScomprimé | 4 mg · un comprimé | FT |
| TACROLIMUS MONOHYDRATÉcomprimé | 4,08 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.